Lineage Cell Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Comprehensive Loss
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| NET LOSS | $(4,789) | $(4,143) |
| Other comprehensive loss: | ||
| Foreign currency translation adjustment, net of tax | (42) | 200 |
| Unrealized loss on marketable debt securities | (9) | (5) |
| COMPREHENSIVE LOSS | (4,840) | (3,948) |
| Comprehensive (income) loss attributable to noncontrolling interest | (23) | 4 |
| COMPREHENSIVE LOSS ATTRIBUTABLE TO LINEAGE COMMON SHAREHOLDERS | $(4,863) | $(3,944) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.